Status:
ENROLLING_BY_INVITATION
Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis
Lead Sponsor:
Dorothy Bautista, MD
Collaborating Sponsors:
Canadian Blood Services
Conditions:
Ligneous Conjunctivitis, Left Eye
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
Allogenic plasma aliquots, used as eye drops, will provide a source of plasminogen in the treatment of ligneous conjunctivitis. The investigational product will be available through written request fr...
Detailed Description
Ligneous conjunctivitis is a chronic progressive disorder of the conjunctival mucosa which occurs secondary to plasminogen deficiency. The condition is characterized by thick, fibrous pseudo membranes...
Eligibility Criteria
Inclusion
- Subject diagnosed with ligneous conjunctivitis associated with Type 1 plasminogen deficiency
Exclusion
- Subject has concurrent eye disease which prevents use of the investigational drug
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04275232
Start Date
May 1 2025
End Date
October 1 2025
Last Update
November 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial University of Newfoundland
St. John's, Newfoundland and Labrador, Canada, A1B 3V6